GLP-1 receptor agonists reduce alcohol consumption and craving
Summary
Preclinical work in rodents and non-human primates has consistently shown GLP-1 agonists reduce alcohol self-administration via mesolimbic reward pathways. Observational pharmacoepidemiology (large EHR cohorts, Swedish/Danish registries) shows lower AUD-related hospitalization in GLP-1 users vs matched controls. The pivotal randomized evidence is a 2025 phase 2 RCT of semaglutide in AUD (Leggio/Chukwueke et al., JAMA Psychiatry) showing reduced drinks per drinking day and craving, though not heavy drinking days as primary outcome. Multiple phase 2/3 RCTs are ongoing. No regulatory body has yet approved a GLP-1 for AUD; guidelines (APA, NIAAA) do not list them as recommended therapy. Evidence base is promising and biologically plausible but not yet settled consensus.
Five-score assessment
Scope
- Pediatric populations
- As first-line FDA-approved AUD therapy
- Non-alcohol substance use disorders (separate evidence base)
Evidence sources
Supporting (3)
-
Low-dose semaglutide reduced drinks per drinking day, weekly alcohol craving, and cigarettes/day in adults with AUD vs placebo over 9 weeks.
-
Systematic review finds consistent reductions in alcohol intake in rodent/primate models and early human signals across exenatide, liraglutide, and semaglutide studies.
-
meta Wium-Andersen et al. 2024 — GLP-1 agonists and alcohol-related outcomes, Danish registry cohort ↗Population-based cohort found GLP-1 agonist initiation associated with lower risk of alcohol-related hospital contacts vs comparator diabetes drugs.
Neutral / context (1)
-
trial_registry NCT05520775 — Semaglutide in AUD ↗Ongoing RCT evaluating semaglutide's effect on alcohol consumption in treatment-seeking AUD patients; results pending.